PapGene Inc. is a biotechnology company focused on improving human health through the development and commercialization of cancer diagnostics products. The Company is developing genetic cytology-based tests for the early detection of cancers based on detecting genetic mutations in cells collected and transported by body fluids. The Company uses advanced genetic sequencing techniques and proprietary bioinformatics software as part of its core technology platform. Powered by error-reducing Safe-SeqS technology licensed from Johns Hopkins University, the proprietary technology can reliably distinguish the rare, genuine mutations indicative of cancers from technical artifacts.
